Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of clomiphene citrate, pioglitazone, and metformin used for treating infertility in women with polycystic ovary syndrome (PCOS), particularly those who are resistant to clomiphene citrate alone. Each component has a different mechanism of action: 1. **Clomiphene citrate**: stimulates ovulation by acting as a selective estrogen receptor modulator. 2. **Pioglitazone**: improves insulin sensitivity by acting as a thiazolidinedione (PPAR-γ agonist). 3. **Metformin**: reduces insulin resistance by acting as a biguanide (AMPK activator).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clomiphene citrate + pioglitazone + metformin.